The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Open accessAbstract
HLA-C*08:02-restricted tumor-infiltrating lymphocytes that were composed of four different T-cell clonotypes that specifically targeted KRAS G12D. However, one of these lesions had progressed on evaluation 9 months after therapy. The lesion was resected and found to have lost the chromosome 6 haplotype encoding the HLA-C*08:02 class I major histocompatibility complex (MHC) molecule. The loss of expression of this molecule provided a direct mechanism of tumor immune evasion. Thus, the infusion of CD8+ cells targeting mutant KRAS mediated effective antitumor immunotherapy against a cancer that expressed mutant KRAS G12D and HLA-C*08:02.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This approach has shown efficacy in colon cancer and NSCLC patients with mutant KRAS G12D and HLA-C*08:02 expression [88].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [88]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Tumors with mutant KRAS can express neoantigen fragments containing the oncogenic driver mutation on the major histocompatibility complex [88,89].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [88]
In the citing paper
“CD8+ TILs and TCRs in CD4+ T cells have been found to specifically recognize KRAS-related mutations, which can be further used to engineer T cells.604,605”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [604]
In the citing paper
“As noted above, peptides derived from KRASG12 variants193,194, and also from KRASQ61H/L/R (ref.198), have been demonstrated to be presented on the surface of malignant cells by various MHC I (HLA-A) molecules.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“ACT with these specific TILs resulted in regression of all seven pulmonary metastases in a patient with KRASG12D-mutant CRC from whom they had been isolated193.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“Notably, loss of MHC was identified as an immune-evasion mechanism in a tumour that progressed 9 months after TIL infusion193.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“Endogenous immune responses against KRAS-mutant cancer cells were first described in 2016 by Tran et al.193, who identified CD8+ TILs with T cell receptors (TCRs) that recognize MHC I (HLA-C*08:02)-presented peptide neoepitopes derived from KRASG12D.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“Using CD8+ T cells that were reactive to KRASG12D mutant, a patient with CRC experienced prolonged partial response [64].”
From KRAS, a New Target for Precision Medicine in Colorectal Cancer? (2024) · cites this paper as [64]
In the citing paper
“It was found that CD8+ T cells, possessing HLA-C08:02-restricted T-cell receptors, specifically recognize the mutant KRASG12D.”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [106]
In the citing paper
“Following the intravenous administration of expanding TCRs in an ex vivo environment, a complete response was observed in lung lesions, resulting in prolonged PFS.”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [106]
In the citing paper
“A recent publication presented the relationship between the KRASG12D mutation and TCRs in a patient diagnosed with metastatic mCRC with lung metastasis [106].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [106]
In the citing paper
“Despite the rarity of HLA-C*08:02, this study demonstrated the promise of T-cell–based immunotherapy for targeting KRASG12D and HLA-C*08:02.”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [44]
In the citing paper
“Tran and colleagues described a case of a patient with metastatic colorectal cancer treated with autologous T cells specific for mutant KRASG12D, which was restricted to the major histocompatibility complex class I allele HLA-C*08:02 (44).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [44]
In the citing paper
“The anti-tumor activity of ICB has been shown to depend on CD8+ T cell, HLA class I–dependent immune activity (34–36).”
From Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy (2018) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839
Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,208
Self-citationCancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y., Dudley, M. E., Wunderlich, J. R., Somerville, R. P. T., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,737
Self-citationDudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U. S., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,625
Self-citationAllele-specific copy number analysis of tumors
Loo, P. V., Nord, S., Lingjærde, O. C., Russnes, H. G., Rye, I. H., Sun, W., Weigman, V., Marynen, P., Zetterberg, A., Naume, B., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009843107 · Cited by 1,192
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 1,002
Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal
Bianchi, V., Harari, A., & Coukos, G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01215 · Cited by 47
Concise Review: Human Pluripotent Stem Cells to Produce Cell-Based Cancer Immunotherapy
Huang, Z., Lai, Y.-S., Li, Y., Blum, R. H., & Kaufman, D. S. (2017) · Stem Cells · doi:10.1002/stem.2754 · Cited by 48
Checkpoints and beyond – Immunotherapy in colorectal cancer
Gutting, T., Burgermeister, E., Härtel, N., & Ebert, M. P. A. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.04.003 · Cited by 48
An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines
Ott, P. A., Dotti, G., Yee, C., & Goff, S. L. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238001 · Cited by 48
Neoantigens in Hematologic Malignancies
Biernacki, M. A., & Bleakley, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00121 · Cited by 47
Mutated RAS: Targeting the “Untargetable” with T Cells
Chatani, P. D., & Yang, J. C. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2138 · Cited by 45
Peptide Delivery Systems for Cancer Vaccines
He, X., Abrams, S. I., & Lovell, J. F. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800060 · Cited by 45
Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1
Smith, K. N., Llosa, N. J., Cottrell, T. R., Siegel, N. M., Fan, H., Suri, P., Chan, H. Y., Guo, H., Oke, T. F., Awan, A. H., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0492-x · Cited by 45
Current Status of Immunotherapies for Treating Pancreatic Cancer
Wu, A. A., Jaffee, E. M., & Lee, V. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0811-5 · Cited by 47
Colorectal cancer: A paradigmatic model for cancer immunology and immunotherapy
Ijsselsteijn, M. E., Pamplona, R. S., Hermitte, F., & de Miranda, N. F. C. C. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.05.003 · Cited by 48
He, R., Lao, Y., Yu, W., Zhang, X., Jiang, M., & Zhu, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.764618 · Cited by 46
Neoantigen-targeted TCR-T cell therapy for solid tumors: How far from clinical application
Xu, R., Du, S., Zhu, J., Meng, F., & Liu, B. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215840 · Cited by 45
Interaction between microbiota and immunity and its implication in colorectal cancer
Xing, C., Du, Y., Duan, T., Nim, K., Chu, J., Wang, H. Y., & Wang, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.963819 · Cited by 47
Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy
Boumelha, J., Molina‐Arcas, M., & Downward, J. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3655 · Cited by 44
Link, J. M., Eng, J. R., Pelz, C., Hawthorne, K., Worth, P. J., Sivagnanam, S., Keith, D., Owen, S., Langer, E. M., Grossblatt-Wait, A., et al. (2025) · Nature Cancer · doi:10.1038/s43018-024-00881-3 · Cited by 44
TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class Ilow cancers
Marijt, K. A., Doorduijn, E. M., & van Hall, T. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.03.029 · Cited by 45
Why do proteases mess up with antigen presentation by re-shuffling antigen sequences?
Liepe, J., Ovaa, H., & Mishto, M. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.04.016 · Cited by 44
Correale, P., Saladino, R. E., Giannarelli, D., Giannicola, R., Agostino, R. M., Staropoli, N., Strangio, A., Giudice, T. D., Nardone, V., Altomonte, M., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000733 · Cited by 43
KRAS inhibition in non–small cell lung cancer: Past failures, new findings and upcoming challenges
Passiglia, F., Malapelle, U., Re, M. D., Righi, L., Pagni, F., Furlan, D., Danesi, R., Troncone, G., & Novello, S. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.06.023 · Cited by 43
T-Cell Transfer Therapy Targeting Mutant KRAS
Maoz, A., Rennert, G., & Gruber, S. B. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1616637 · Cited by 43
Levin, N., Kim, S. P., Marquardt, C., Vale, N. R., Yu, Z., Sindiri, S., Gartner, J. J., Parkhurst, M. R., Krishna, S., Lowery, F. J., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008645 · Cited by 42
Self-citationShi, L., Zhang, Y., Feng, L., Wang, L., Rong, W., Wu, F., Wu, J., Zhang, K., & Cheng, S. (2017) · Oncotarget · doi:10.18632/oncotarget.16758 · Cited by 42
Martin, D., Rödel, F., Balermpas, P., Rödel, C. M., & Fokas, E. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.05.001 · Cited by 42
Bräunlein, E., & Krackhardt, A. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01702 · Cited by 43
Adoptive T Cell Therapy: New Avenues Leading to Safe Targets and Powerful Allies
Hammerl, D., Rieder, D., Martens, J. W. M., Trajanoski, Z., & Debets, R. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.09.004 · Cited by 46
DNT Cell-based Immunotherapy: Progress and Applications
Li, Y., Dong, K., Fan, X., Xie, J., Wang, M., Fu, S., & Li, Q. (2020) · Journal of Cancer · doi:10.7150/jca.39717 · Cited by 43
Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors
Olbryt, M., Rajczykowski, M., & Widłak, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114071 · Cited by 42
Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside
Roy, S., Sethi, T. K., Taylor, D., Kim, Y. J., & Johnson, D. B. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5bt0420-585rr · Cited by 44
The Current Lung Cancer Neoantigen Landscape and Implications for Therapy
Ye, L., Creaney, J., Redwood, A., & Robinson, B. W. S. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.01.1624 · Cited by 42
Lee, M. Y., Robbins, Y. L., Sievers, C. M., Friedman, J., Sater, H. A., Clavijo, P. E., Judd, N. P., Tsong, E., Silvin, C., Soon‐Shiong, P., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002128 · Cited by 43
Liang, J., Cheng, K., Li, Y., Xu, J., Chen, Y., Ma, N., Feng, Q., Zhu, F., Ma, X., Zhang, T., et al. (2021) · Fundamental Research · doi:10.1016/j.fmre.2021.11.032 · Cited by 42
Parikh, A. Y., Masi, R., Gasmi, B., Hanada, K., Parkhurst, M. R., Gartner, J. J., Sindiri, S., Prickett, T. D., Robbins, P. F., Zacharakis, N., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03476-6 · Cited by 44
Self-citationAttacking Tumors From All Sides: Personalized Multiplex Vaccines to Tackle Intratumor Heterogeneity
Fennemann, F. L., de Vries, I. J. M., Figdor, C. G., & Verdoes, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00824 · Cited by 41
Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer
Zheng, Y., Fu, Y., Wang, P., & Ding, Z. (2022) · Disease Markers · doi:10.1155/2022/8270305 · Cited by 41
Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer
Janssen, J. B. E., Medema, J. P., Gootjes, E. C., Tauriello, D. V. F., & Verheul, H. M. W. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102433 · Cited by 42
Ye, B., Smerin, D., Qingping, G., Kang, C., & Xiong, X. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.12.017 · Cited by 41
Identifying neoantigens for use in immunotherapy
Hutchison, S., & Pritchard, A. L. (2018) · Mammalian Genome · doi:10.1007/s00335-018-9771-6 · Cited by 42
Yu, Y., Shan, N., Li, L., Zhu, Y., Lin, L., Mao, C., Hu, T., Xue, X., Su, X., Shen, X., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03386-7 · Cited by 40
Giannakopoulou, E., Lehander, M., Culleton, S. V., Yang, W., Li, Y., Kärpänen, T., Yoshizato, T., Rustad, E. H., Nielsen, M. M., Bollineni, R. C., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00642-8 · Cited by 41
The Discovery of Biomarkers in Cancer Immunotherapy
George, A. P., Kuzel, T. M., Zhang, Y., & Zhang, B. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.03.015 · Cited by 41
Adoptive Cell Therapy: A Novel and Potential Immunotherapy for Glioblastoma
Wang, J., Shen, F., Yao, Y., Wang, L., Zhu, Y.-J., & Hu, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00059 · Cited by 40
The Anticancer Potential of T Cell Receptor-Engineered T Cells
Ecsedi, M., McAfee, M. S., & Chapuis, A. G. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.09.002 · Cited by 42
B cells in pancreatic cancer stroma
Delvecchio, F. R., Goulart, M. R., Fincham, R. E. A., Bombadieri, M., & Kocher, H. M. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i11.1088 · Cited by 40
Colorectal Cancer Immunotherapy: State of the Art and Future Directions
Cornista, A. M., Giolito, M. V., Baker, K., Hazime, H., Dufait, I., Datta, J., Khumukcham, S. S., De Ridder, M., Roper, J., Abreu, M. T., et al. (2023) · Gastro Hep Advances · doi:10.1016/j.gastha.2023.09.007 · Cited by 39
The potential and promise for clinical application of adoptive T cell therapy in cancer
Li, Y., Zheng, Y., Liu, T., Liao, C., Shen, G., & He, Z. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05206-7 · Cited by 41
John, S., Antonia, S. J., Rose, T. A., Seifert, R. P., Centeno, B. A., Wagner, A. S., & Creelan, B. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0258-x · Cited by 39
Genomic testing for pancreatic cancer in clinical practice as real-world evidence
Hayashi, H., Tanishima, S., Fujii, K., Mori, R., Okamura, Y., Yanagita, E., Matsuoka, R., Amano, T., Kinoshita, I., Komatsu, Y., et al. (2018) · Pancreatology · doi:10.1016/j.pan.2018.07.006 · Cited by 40
Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer
Yu, Y., Zhang, J., Ni, L., Zhu, Y., Yu, H., Teng, Y., Lin, L., Xue, Z., Xue, X., Shen, X., et al. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1891814 · Cited by 40
Neoantigens in precision cancer immunotherapy: from identification to clinical applications
Zhang, Q., Jia, Q., Zhang, J., & Zhu, B. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002181 · Cited by 39
The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers
Tria, S. M., Burge, M. E., & Whitehall, V. L. J. (2023) · Cancers · doi:10.3390/cancers15082375 · Cited by 38
Boosting CAR-T cell therapy through vaccine synergy
Li, Y.-R., Lyu, Z., Shen, X., Fang, Y., & Yang, L. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.12.004 · Cited by 40
Exploring optimal sequencing of radiation and immunotherapy combinations
Gunderson, A. J., & Young, K. H. (2018) · Advances in Radiation Oncology · doi:10.1016/j.adro.2018.07.005 · Cited by 39
Discovery through clinical sequencing in oncology
Donoghue, M. T. A., Schram, A. M., Hyman, D. M., & Taylor, B. S. (2020) · Nature Cancer · doi:10.1038/s43018-020-0100-0 · Cited by 38
Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens
Hwang, M. S., Miller, M. S., Thirawatananond, P., Douglass, J., Wright, K. M., Hsiue, E. H.-C., Mog, B. J., Aytenfisu, T. Y., Murphy, M. B., Azurmendi, P. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25605-4 · Cited by 38
Clinical Application of Adaptive Immune Therapy in MSS Colorectal Cancer Patients
Wang, D., Zhang, H., Xiang, T., & Wang, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.762341 · Cited by 38
Role of FABP5 in T Cell Lipid Metabolism and Function in the Tumor Microenvironment
Jin, R., Hao, J., Yu, J., Wang, P., Sauter, E. R., & Li, B. (2023) · Cancers · doi:10.3390/cancers15030657 · Cited by 38
Jie, C., Li, R., Cheng, Y., Wang, Z., Wu, Q., & Xie, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1122352 · Cited by 37
Challenges and solutions for therapeutic TCR ‐based agents
Malviya, M., Aretz, Z. E. H., Molvi, Z., Lee, J., Pierre, S. A., Wallisch, P., Dao, T., & Scheinberg, D. A. (2023) · Immunological Reviews · doi:10.1111/imr.13233 · Cited by 37
Personalised neoantigen‐based therapy in colorectal cancer
Zhu, Y., Li, X., Chen, T., Wang, J., Zhou, Y., Mu, X., Du, Y., Wang, J., Tang, J., & Liu, J. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1461 · Cited by 37
Targeting Neoantigens in Glioblastoma
Johanns, T. M., Bowman-Kirigin, J. A., Liu, C. J., & Dunn, G. P. (2017) · Neurosurgery · doi:10.1093/neuros/nyx321 · Cited by 37
KRAS-Driven Lung Adenocarcinoma and B Cell Infiltration: Novel Insights for Immunotherapy
Rosamaria, P., Petriella, D., Lacalamita, R., Montrone, M., Catino, A., Pizzutilo, P., Antonietta, B. M., Zito, A. F., Bene, G. D., Zonno, A., et al. (2019) · Cancers · doi:10.3390/cancers11081145 · Cited by 37
Gastman, B., Agarwal, P. K., Berger, A., Boland, G. M., Broderick, S., Butterfield, L. H., Byrd, D. R., Fecci, P. E., Ferris, R. L., Fong, Y., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001583 · Cited by 39
Self-citationKroemer, M., Turco, C., Spehner, L., Viot, J., Idirène, I., Bouard, A., Renaude, E., Deschamps, M., Godet, Y., Adotévi, O., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001478 · Cited by 37
Defining Immunogenic and Radioimmunogenic Tumors
Medler, T. R., Blair, T. C., Crittenden, M. R., & Gough, M. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.667075 · Cited by 38
MAIT Cells: Partners or Enemies in Cancer Immunotherapy?
Cogswell, D. T., Gapin, L., Tobin, H., McCarter, M. D., & Tobin, R. P. (2021) · Cancers · doi:10.3390/cancers13071502 · Cited by 37
Schrörs, B., Lübcke, S., Lennerz, V., Fatho, M., Bicker, A., Wölfel, C., Derigs, P., Hankeln, T., Schadendorf, D., Paschen, A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16048 · Cited by 37
Robinson, W., Stone, J. K., Schischlik, F., Gasmi, B., Kelly, M. C., Seibert, C., Dadkhah, K., Gertz, E. M., Lee, J. S., Zhu, K., et al. (2024) · Science Advances · doi:10.1126/sciadv.adj7402 · Cited by 37
Making It Personal: Neoantigen Vaccines in Metastatic Melanoma
Hellmann, M. D., & Snyder, A. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.001 · Cited by 37
Activating the Nucleic Acid-Sensing Machinery for Anticancer Immunity
Medler, T. R., Patel, J. M., Alice, A. F., Baird, J. R., Hu, H., & Gough, M. J. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.08.006 · Cited by 36
Targeting MSS colorectal cancer with immunotherapy: are we turning the corner?
Wang, C., & Fakih, M. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1933940 · Cited by 36
Perspectives on Immunotherapy of Metastatic Colorectal Cancer
Dai, Y., Zhao, W., Yue, L., Dai, X., Rong, D., Wu, F., Gu, J., & Qian, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.659964 · Cited by 37
Update on Targeted Therapy in Medullary Thyroid Cancer
Okafor, C. I., Hogan, J., Raygada, M. J., Thomas, B. J., Akshintala, S., Glod, J. W., & Rivero, J. D. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.708949 · Cited by 36
Time 2EVOLVE: predicting efficacy of engineered T-cells – how far is the bench from the bedside?
Guedan, S., Luu, M., Ammar, D., Barbao, P., Bonini, C., Bousso, P., Buchholz, C. J., Casucci, M., Angelis, B. D., Donnadieu, E., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003487 · Cited by 38
Advances in immunotherapy for MMR proficient colorectal cancer
Lote, H., Starling, N., Pihlak, R., & Gerlinger, M. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102480 · Cited by 36
IL17A Regulates Tumor Latency and Metastasis in Lung Adeno and Squamous SQ.2b and AD.1 Cancer
You, R., DeMayo, F. J., Liu, J., Cho, S.-N., Burt, B. M., Creighton, C. J., Casal, R. F., Lazarus, D. R., Lu, W., Tung, H.-Y., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0554 · Cited by 36
Gu, M., Gao, Y., & Chang, P. (2021) · Cancers · doi:10.3390/cancers13102429 · Cited by 35
Ramirez-Valdez, R. A., Baharom, F., Khalilnezhad, A., Fussell, S. C., Hermans, D., Schrager, A. M., Tobin, K. K. S., Lynn, G. M., Khalilnezhad, S., Ginhoux, F., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112599 · Cited by 37
Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumors
Bear, A. S., Nadler, R. B., O’Hara, M. H., Stanton, K. L., Xu, C. B., Saporito, R., Rech, A. J., Baroja, M. L., Blanchard, T., Elliott, M. H., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci175790 · Cited by 35
A review of immune therapy in cancer and a question: can thermal therapy increase tumor response?
Bull, J. M. (2017) · International Journal of Hyperthermia · doi:10.1080/02656736.2017.1387938 · Cited by 37
Current Options and Future Directions in Immune Therapy for Glioblastoma
Lynes, J. P., Sánchez, V., Dominah, G. A., Nwankwo, A., & Nduom, E. K.-E. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00578 · Cited by 36
Microbiota: Overview and Implication in Immunotherapy-Based Cancer Treatments
Brandi, G., & Frega, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112699 · Cited by 36
New emerging targets in cancer immunotherapy: the role of neoantigens
Mattos‐Arruda, L. D., Blanco-Heredia, J., Aguilar‐Gurrieri, C., Carrillo, J., & Blanco, J. (2019) · ESMO Open · doi:10.1136/esmoopen-2020-000684 · Cited by 35
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
Hu‐Lieskovan, S., Bhaumik, S., Dhodapkar, K. M., Grivel, J., Gupta, S. V., Hanks, B. A., Janetzki, S., Kleen, T. O., Koguchi, Y., Lund, A. W., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000705 · Cited by 35
Olsen, H. E., Lynn, G. M., Valdes, P. A., Cerecedo-Lopez, C. D., Ishizuka, A. S., Arnaout, O. M., Bi, W. L., Peruzzi, P. P., Chiocca, E. A., Friedman, G. K., et al. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab027 · Cited by 35
Quantifying the limits of CAR T-cell delivery in mice and men
Brown, L., Gaffney, E. A., Ager, A., Wagg, J., & Coles, M. C. (2021) · Journal of The Royal Society Interface · doi:10.1098/rsif.2020.1013 · Cited by 35
Identification and Targeting of Mutant Peptide Neoantigens in Cancer Immunotherapy
Verdon, D. J., & Jenkins, M. R. (2021) · Cancers · doi:10.3390/cancers13164245 · Cited by 36
Targeting RAS mutants in malignancies: successes, failures, and reasons for hope
Yang, H. S., Zhou, X., Fu, D., Le, C., Wang, J., Zhou, Q., Liu, X., Yuan, Y., Ding, K., & Xiao, Q. (2022) · 癌症：英文版 · doi:10.1002/cac2.12377 · Cited by 38
Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer
Aka, A. A., Rappaport, J. A., Pattison, A. M., Sato, T., Snook, A. E., & Waldman, S. A. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1292124 · Cited by 35
RAS signaling and immune cells: a sinister crosstalk in the tumor microenvironment
Liu, Y., Xie, B., & Chen, Q. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04486-9 · Cited by 36
Huang, D., Li, Y., Rui, W., Sun, K., Zhou, Z., Lv, X., Li, Y., Chen, J., Zhou, J., Liu, V., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114949 · Cited by 36
Art of TIL immunotherapy: SITC’s perspective on demystifying a complex treatment
Turcotte, S., Donia, M., Gastman, B., Besser, M. J., Brown, R., Coukos, G., Creelan, B., Mullinax, J. E., Sondak, V. K., Yang, J. C.-H., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010207 · Cited by 34
Kim, Y. J., Chambers, A. G., Cecchi, F., & Hembrough, T. (2018) · Journal of Proteomics · doi:10.1016/j.jprot.2018.04.022 · Cited by 34
Acquired resistance to immunotherapy in MMR-D pancreatic cancer
Hu, Z. I., Hellmann, M. D., Wolchok, J. D., Vyas, M., Shia, J., Stadler, Z. K., Diaz, L. A., & O'Reilly, E. M. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0448-1 · Cited by 34
Large-scale expansion and characterization of CD3+ T-cells in the Quantum® Cell Expansion System
Coeshott, C. M., Vang, B., Jones, M., & Nankervis, B. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2001-5 · Cited by 35
Gokuldass, A., Draghi, A., Papp, K., Borch, T. H., Nielsen, M., Westergaard, M. C. W., Andersen, R. S., Schina, A., Bol, K. F., Chamberlain, C. A., et al. (2020) · Cancers · doi:10.3390/cancers12113344 · Cited by 34
Targeting KRAS in Colorectal Cancer
Wang, C., & Fakih, M. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01022-0 · Cited by 35
Hirama, T., Tokita, S., Nakatsugawa, M., Murata, K., Nannya, Y., Matsuo, K., Inoko, H., Hirohashi, Y., Hashimoto, S., Ogawa, S., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.146356 · Cited by 34
Qi, Y. A., Maity, T. K., Cultraro, C. M., Misra, V., Zhang, X., Ade, C. M., Gao, S., Milewski, D., Nguyen, K. D. P., Ebrahimabadi, M. H., et al. (2021) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2021.100136 · Cited by 36
Peri, A., Greenstein, E., Alon, M., Pai, J. A., Dingjan, T., Reich-Zeliger, S., Barnea, E., Barbolin, C., Levy, R., Arnedo-Pac, C., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci129466 · Cited by 36
Self-citationPersonalized Immunotherapy in Colorectal Cancers: Where Do We Stand?
Hu, L., Lan, H., Huang, D., Li, X., & Jin, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.769305 · Cited by 34
Metadata
- Authors
- Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., Kriley, I. R., & Rosenberg, S. A.
- Affiliations
- National Institutes of Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-12-08
- Volume
- 375
- Issue
- 23
- Pages
- 2255-2262
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5178827
- OpenAlex
- W2559953355
- Cited by
- 1,368
- References
- 27
- Citations by year
- 2026: 96 · 2025: 132 · 2024: 129 · 2023: 162 · 2022: 162 · 2021: 183 · 2020: 149 · 2019: 134 · 2018: 118 · 2017: 98 · 2016: 3
- FWCI
- 71.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (Z01BC010984)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- tumor-infiltrating lymphocytes, mutant KRAS, KRAS G12D, CD8+ T cells, tumor immune evasion, MHC class I loss, cancer immunotherapy
- MeSH terms
- Female, Flow Cytometry, Humans, Lung, Lung Neoplasms, Middle Aged, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), CD8-Positive T-Lymphocytes, Lymphocyte Count
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
